Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell Therapy

Blood (2023) 142 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2023-187096

Published: 2023

Journal Articles

Identification of Healthy Donor Phenotypic and Functional Signatures That Predict Allogeneic, Hypoimmune CD19-Directed CAR T Cell Potency

Blood (2023) 142 (Supplement 1): 6810.

https://doi.org/10.1182/blood-2023-188264

Published: 2023

Journal Articles

Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T Cells

Darin Salloum, PhD, Kavita Tundwal, Divy Kangeyan, PhD, Adam Johnson, Neal van Hoeven, PhD, Brian Granger, Jesus Moreno, Ouwen Liang, Pascal Beauchesne, Terry J. Fry, Aaron Foster

Blood (2022) 140 (Supplement 1): 4524–4525.

https://doi.org/10.1182/blood-2022-168372

Published: 2022

Journal Articles

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

Jeremy M. Kinder, Chanel Athena-Estrada, Danyal Malik, Xiaomeng Hu, Meghan Lamba, Chi Young, Neal Van Hoeven, Brian Granger, Vandana Chaturvedi, Ouwen Liang, Jesus Moreno, Aaron Lampano, Garrett Zipp, Adam Johnson, Terry Fry, Sonja Schrepfer, Aaron Foster

Blood (2022) 140 (Supplement 1): 7120–7121.

https://doi.org/10.1182/blood-2022-166845

Published: 2022

Journal Articles

CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies

Jesse Green, Adam Johnson, Brian Granger, Ouwen Liang, Jesus Moreno, Andrew Tucker, Hallee Wright, Brian Dolinski, Hanane Ennajdaoui, Semih Tareen, Neal van Hoeven, PhD, Jagesh Shah, Kutlu Elpek, Aaron Foster, Terry J. Fry

Blood (2022) 140 (Supplement 1): 7768–7769.

https://doi.org/10.1182/blood-2022-162705

Published: 2022

Journal Articles

A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape

Adam Johnson, Hallee Wright, Xiaomeng Hu, Neal van Hoeven, PhD, Brian Granger, Ouwen Liang, Jesus Moreno, Meghan Lamba, Chi Young, Andrew McAlister, Terry J. Fry, Sonja Schrepfer, Aaron Foster

Blood (2022) 140 (Supplement 1): 4552–4553.

https://doi.org/10.1182/blood-2022-168251

Published: 2022

Journal Articles

CD4-Targeted Fusosomes Are Capable of Transducing Resting T Helper Cells to Generate Highly Potent CAR-T Cells

Christie Ciarlo, Zach Frye, Andre DeGroot, Walter Flores, Kutlu Elpek, Lauren Pepper, Adam Johnson, Jagesh V Shah, Aaron E. Foster, Terry J. Fry

Blood (2021) 138 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2021-148469

Published: 2021

Journal Articles

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Colleen Annesley, MD, Rebecca Gardner, MD, Ashley Wilson, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Qian Vicky Wu, PhD, Adam Brand, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2019) 134 (Supplement_1): 223.

https://doi.org/10.1182/blood-2019-131346

Published: 2019

Journal Articles

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Colleen Annesley, MD, Rebecca Gardner, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4021.

https://doi.org/10.1182/blood-2018-99-112285

Published: 2018

Journal Articles

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Rebecca Gardner, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Kaelin Crews, Lauren Huang, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Karen Spratt, PhD, Josh Gustafson, PhD, Adam Johnson, PhD, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 278.

https://doi.org/10.1182/blood-2018-99-113126

Published: 2018

NARROW

Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell Therapy

Identification of Healthy Donor Phenotypic and Functional Signatures That Predict Allogeneic, Hypoimmune CD19-Directed CAR T Cell Potency

Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T Cells

BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies

A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape

CD4-Targeted Fusosomes Are Capable of Transducing Resting T Helper Cells to Generate Highly Potent CAR-T Cells

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only